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In this issue of Blood, Lancet et al report their findings that CPX-351, a liposomal formulation of cytarabine and daunorubicin in a 5:1 molar ratio, produces superior response rates compared with 713 in older patients with acute myeloid leukemia (AML).
1
T he management of AML poses many therapeutic challenges. 713, defined as 7 days of cytarabine and 3 days of an anthracycline, was initially established as a standard induction regimen for newly diagnosed AML patients in the early 1980s after several large cooperative group trials by the Cancer and Leukemia Group B demonstrated its efficacy. 2 However, a critical dilemma that continues to frustrate those who treat AML is how best to manage older AML patients ($55 years) and those with secondary AML. These subgroups of patients respond poorly to induction chemotherapy, frequently develop toxicities and complications from chemotherapy, and are rarely cured with standard therapeutic regimens. Of keen interest were the promising results seen in patients with secondary AML. Secondary AML (treatment-related AML or AML from a preexisting hematologic disorder) has a dismal outcome with 713. Lancet et al demonstrate not only superior CR rates, but also prolonged overall survival (OS) and a signal of improved event-free survival (EFS) in secondary AML patients treated with CPX-351 as shown in the figure, although this subanalysis will need to be confirmed in a larger phase 3 trial. This may significantly advance our therapeutic armamentarium for AML, as secondary AML is a feature that can be gleaned on history alone, as opposed to waiting for other poorrisk features such as cytogenetics/genetic markers. Providing these patients with a therapeutic alternative to 713 would be a considerable achievement. For 
